Hypertension results due to dysfunction of different metabolic pathways leading to the increased risk of cerebral ischemia, atherosclerosis, cardiovascular and inflammatory disorders. Hypertension has been considered a one of the major contributors to metabolic syndrome and is often referred to as a ‘silent killer’. Its incidence is on the rise across the globe owing to the drastic life style changes. The diagnosis of hypertension had been traditionally carried out through measurement of systolic and diastolic blood pressure but in most cases, this form of diagnosis is too late and the disease has already caused organ damage. Therefore, early detection of hypertension by monitoring subtle changes in specific biochemical markers from body fluids can minimize the risk of organ damage. However, a single marker may be insufficient for accurate diagnosis of hypertension thereby necessitating quantification of multiple markers. Concerted efforts to identify key markers for hypertension and their quantification, especially using chemical and biosensors, are underway in different parts of the world. Constant evolution of the sensing elements and transduction strategies have contributed to significant improvements in the diagnosis field, especially in the context of sensitivity, response time and selectivity and this when applied to the detection of hypertension markers may prove beneficial. This review summarizes advances in the field of sensor technology towards the detection of biologically relevant entities, arrays and the next generation ‘lab-on-a-chip’ systems for hypertension.

由于不同代谢途径的功能障碍导致高血压，导致脑缺血，动脉粥样硬化，心血管疾病和炎性疾病的风险增加。高血压被认为是代谢综合征的主要诱因之一，通常被称为“沉默杀手”。由于生活方式的急剧变化，其发病率在全球范围内呈上升趋势。高血压的诊断传统上是通过测量收缩压和舒张压来进行的，但在大多数情况下，这种诊断形式为时已晚，该疾病已经引起器官损害。因此，通过监测体液中特定生化标志物的细微变化来及早发现高血压，可以最大程度地降低器官损害的风险。然而，单一标记可能不足以准确诊断高血压，因此需要对多个标记进行定量。在世界不同地区，人们正在共同努力，特别是使用化学和生物传感器，来确定高血压的关键标志物及其定量方法。传感元件和转导策略的不断发展已在诊断领域做出了重大改进，尤其是在灵敏度，响应时间和选择性方面，这在应用于高血压标志物检测时可能被证明是有益的。这篇综述总结了传感器技术领域在检测与生物有关的实体，阵列和用于高血压的下一代“芯片实验室”系统方面的进展。